Rhumbline Advisers lifted its position in Horizon Pharma PLC (NASDAQ:HZNP) by 5.2% during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 221,853 shares of the biopharmaceutical company’s stock after purchasing an additional 11,010 shares during the quarter. Rhumbline Advisers owned about 0.14% of Horizon Pharma worth $2,813,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. Russell Investments Group Ltd. increased its holdings in shares of Horizon Pharma by 82.8% in the second quarter. Russell Investments Group Ltd. now owns 153,668 shares of the biopharmaceutical company’s stock worth $1,824,000 after purchasing an additional 69,626 shares during the period. Neuberger Berman Group LLC bought a new position in shares of Horizon Pharma in the second quarter worth $7,147,000. Ameriprise Financial Inc. bought a new position in shares of Horizon Pharma in the second quarter worth $4,865,000. Bank of New York Mellon Corp increased its holdings in shares of Horizon Pharma by 19.7% in the second quarter. Bank of New York Mellon Corp now owns 915,421 shares of the biopharmaceutical company’s stock worth $10,866,000 after purchasing an additional 150,850 shares during the period. Finally, Sei Investments Co. increased its holdings in shares of Horizon Pharma by 68.5% in the third quarter. Sei Investments Co. now owns 391,170 shares of the biopharmaceutical company’s stock worth $4,961,000 after purchasing an additional 159,002 shares during the period. 86.59% of the stock is currently owned by hedge funds and other institutional investors.

Shares of Horizon Pharma PLC (HZNP) opened at $14.90 on Friday. The company has a debt-to-equity ratio of 1.89, a quick ratio of 1.52 and a current ratio of 1.64. Horizon Pharma PLC has a 1 year low of $9.45 and a 1 year high of $18.31. The stock has a market cap of $2,441.90, a PE ratio of 10.80, a price-to-earnings-growth ratio of 1.26 and a beta of 1.31.

Horizon Pharma (NASDAQ:HZNP) last posted its quarterly earnings results on Monday, November 6th. The biopharmaceutical company reported $0.26 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.22 by $0.04. Horizon Pharma had a negative net margin of 45.28% and a positive return on equity of 20.22%. The business had revenue of $271.60 million during the quarter, compared to analyst estimates of $259.74 million. During the same period in the prior year, the business posted $0.70 earnings per share. The company’s revenue was up 30.1% on a year-over-year basis. equities research analysts anticipate that Horizon Pharma PLC will post 0.72 EPS for the current year.

A number of research firms recently commented on HZNP. Cantor Fitzgerald set a $17.00 target price on Horizon Pharma and gave the company a “buy” rating in a research note on Friday, December 1st. UBS set a $20.00 target price on Horizon Pharma and gave the company a “buy” rating in a research note on Thursday, November 30th. Jefferies Group increased their target price on Horizon Pharma from $16.00 to $21.00 and gave the company a “buy” rating in a research note on Tuesday, November 7th. Stifel Nicolaus reissued a “buy” rating and issued a $20.00 target price on shares of Horizon Pharma in a research note on Sunday, October 22nd. Finally, ValuEngine raised Horizon Pharma from a “hold” rating to a “buy” rating in a research note on Monday, October 16th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and eleven have assigned a buy rating to the company. Horizon Pharma currently has a consensus rating of “Buy” and a consensus target price of $18.75.

ILLEGAL ACTIVITY WARNING: “Horizon Pharma PLC (HZNP) Shares Bought by Rhumbline Advisers” was reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this report on another domain, it was illegally stolen and republished in violation of US & international trademark & copyright laws. The legal version of this report can be accessed at https://www.thecerbatgem.com/2017/12/10/horizon-pharma-plc-hznp-shares-bought-by-rhumbline-advisers.html.

Horizon Pharma Profile

Horizon Pharma Public Limited Company is a biopharmaceutical company. The Company is focused on identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs. As of December 31, 2016, the Company marketed 11 medicines through its orphan, rheumatology and primary care business units.

Institutional Ownership by Quarter for Horizon Pharma (NASDAQ:HZNP)

Receive News & Stock Ratings for Horizon Pharma PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Pharma PLC and related stocks with our FREE daily email newsletter.